EA201991788A1 - Улучшенные моноклональные анти-vegr-2 антитела - Google Patents
Улучшенные моноклональные анти-vegr-2 антителаInfo
- Publication number
- EA201991788A1 EA201991788A1 EA201991788A EA201991788A EA201991788A1 EA 201991788 A1 EA201991788 A1 EA 201991788A1 EA 201991788 A EA201991788 A EA 201991788A EA 201991788 A EA201991788 A EA 201991788A EA 201991788 A1 EA201991788 A1 EA 201991788A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- monoclonal anti
- antibody
- vegr
- antibodies
- improved monoclonal
- Prior art date
Links
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 abstract 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000005094 computer simulation Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к технической области биомедицины. Предложено улучшенное моноклональное анти-VEGFR-2 (рецептора 2 фактора роста эндотелия сосудов) и его применение. Посредством метода компьютерного моделирования разработана новая фаговая библиотека антител, и после нескольких раундов скрининга получено улучшенное моноклональное анти-VEGR-2 антитело. И аффинность, и биологическая активность указанного антитела выше, чем у исходного антитела. Указанное антитело способно эффективно ингибировать связывание VEGFR-2 и его лиганда, VEGF (фактор роста эндотелия сосудов), in vitro и может быть использовано в лечении опухоли и заболевания, вызванного ангиогенезом, такого как макулярная дегенерация.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710130518.0A CN106674349B (zh) | 2017-03-07 | 2017-03-07 | 一种改进的抗vegfr‑2单克隆抗体 |
PCT/CN2018/076847 WO2018161798A1 (zh) | 2017-03-07 | 2018-02-14 | 一种改进的抗vegfr-2单克隆抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991788A1 true EA201991788A1 (ru) | 2020-02-28 |
Family
ID=58828620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991788A EA201991788A1 (ru) | 2017-03-07 | 2018-02-14 | Улучшенные моноклональные анти-vegr-2 антитела |
Country Status (9)
Country | Link |
---|---|
US (1) | US11370834B2 (ru) |
EP (1) | EP3590964A4 (ru) |
JP (1) | JP6843262B2 (ru) |
KR (1) | KR102276489B1 (ru) |
CN (1) | CN106674349B (ru) |
AU (1) | AU2018229915B2 (ru) |
CA (1) | CA3054615C (ru) |
EA (1) | EA201991788A1 (ru) |
WO (1) | WO2018161798A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106674349B (zh) | 2017-03-07 | 2018-03-13 | 北京东方百泰生物科技有限公司 | 一种改进的抗vegfr‑2单克隆抗体 |
WO2021013061A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 一种人源化抗vegfr2抗体及其应用 |
CN111024949A (zh) * | 2019-12-31 | 2020-04-17 | 上海博威生物医药有限公司 | 一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用 |
CN112094351B (zh) * | 2020-09-11 | 2021-04-20 | 北京东方百泰生物科技股份有限公司 | 一种抗vegfr-2单克隆抗体的检测性抗体、应用及检测方法 |
CN115724968B (zh) * | 2021-08-27 | 2023-08-08 | 三优生物医药(上海)有限公司 | Vegf结合分子及其用途 |
CN115957319B (zh) * | 2022-10-14 | 2023-06-30 | 北京东方百泰生物科技股份有限公司 | 一种抗nkg2a单克隆抗体的注射制剂 |
CN116254315A (zh) * | 2022-12-23 | 2023-06-13 | 北京东方百泰生物科技股份有限公司 | 一种vegf/vegfr抑制剂生物学活性的检测方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE510561T1 (de) * | 2002-03-04 | 2011-06-15 | Imclone Llc | Kdr-spezifische menschliche antikörper und ihre verwendung |
CN103012589B (zh) * | 2012-12-11 | 2014-07-16 | 上海赛伦生物技术有限公司 | 人源抗人血管内皮细胞生长因子抗体及其应用 |
CN103965355A (zh) * | 2013-02-06 | 2014-08-06 | 中国医学科学院基础医学研究所 | 针对VEGFR2的全人源抗体重链和轻链可变区及相应Fab和全长抗体 |
CN103965356A (zh) * | 2013-02-06 | 2014-08-06 | 中国医学科学院基础医学研究所 | 针对VEGFR2的全人源抗体重链和轻链可变区及相应Fab和全长抗体 |
CN103333247B (zh) * | 2013-05-30 | 2014-10-08 | 北京东方百泰生物科技有限公司 | 新型抗vegfr2的单克隆抗体及其制备与应用 |
CN103525868B (zh) | 2013-10-17 | 2015-01-21 | 百泰生物药业有限公司 | 哺乳动物细胞高效表达载体的构建及应用 |
CN105646710B (zh) * | 2014-11-17 | 2020-08-25 | 四川科伦博泰生物医药股份有限公司 | 一种全人源化抗vegfr-2单克隆抗体及其制备方法 |
BR112017022205A2 (pt) * | 2015-04-14 | 2018-08-28 | Academia Sinica | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada |
KR20180021136A (ko) * | 2015-06-30 | 2018-02-28 | 헨리우스 바이오테크 컴퍼니 리미티드 | 항-혈관 내피 성장 인자 수용체 2 (vegfr2) 항체 |
CN106674349B (zh) * | 2017-03-07 | 2018-03-13 | 北京东方百泰生物科技有限公司 | 一种改进的抗vegfr‑2单克隆抗体 |
-
2017
- 2017-03-07 CN CN201710130518.0A patent/CN106674349B/zh active Active
-
2018
- 2018-02-14 US US16/487,833 patent/US11370834B2/en active Active
- 2018-02-14 EP EP18764068.5A patent/EP3590964A4/en active Pending
- 2018-02-14 AU AU2018229915A patent/AU2018229915B2/en active Active
- 2018-02-14 WO PCT/CN2018/076847 patent/WO2018161798A1/zh unknown
- 2018-02-14 CA CA3054615A patent/CA3054615C/en active Active
- 2018-02-14 KR KR1020197025428A patent/KR102276489B1/ko active IP Right Grant
- 2018-02-14 EA EA201991788A patent/EA201991788A1/ru unknown
- 2018-02-14 JP JP2019546906A patent/JP6843262B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US11370834B2 (en) | 2022-06-28 |
KR20190113876A (ko) | 2019-10-08 |
JP6843262B2 (ja) | 2021-03-17 |
JP2020510427A (ja) | 2020-04-09 |
CN106674349A (zh) | 2017-05-17 |
AU2018229915B2 (en) | 2020-10-08 |
CA3054615A1 (en) | 2018-09-13 |
US20210139575A1 (en) | 2021-05-13 |
CN106674349B (zh) | 2018-03-13 |
CA3054615C (en) | 2022-08-02 |
AU2018229915A1 (en) | 2019-09-19 |
WO2018161798A1 (zh) | 2018-09-13 |
EP3590964A4 (en) | 2020-03-25 |
EP3590964A1 (en) | 2020-01-08 |
KR102276489B1 (ko) | 2021-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991788A1 (ru) | Улучшенные моноклональные анти-vegr-2 антитела | |
EA201891165A1 (ru) | Молекулы, связывающие pd1 и/или lag3 | |
EA202090812A1 (ru) | Новые биспецифические полипептидные комплексы | |
EA201891166A1 (ru) | Ctla4-связывающие вещества | |
MX2017008662A (es) | Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos. | |
UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
PH12018502560A1 (en) | Anti-c5 antibodies and uses thereof | |
EA201890143A3 (ru) | Антитела против pdgfr-бета и их применения | |
EA201792451A1 (ru) | Антитела к ox40 и способы их применения | |
EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
EA201691027A1 (ru) | Модуляторы aplnr и их применение | |
EA201790530A1 (ru) | Агенты, связывающиеся с cd123, и виды их применения | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
CR20120454A (es) | Proteínas terapéuticas de unión a dll4 | |
EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
EA201892097A1 (ru) | АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ | |
EA202091747A1 (ru) | Составы антитела b7-h4 | |
PH12020550952A1 (en) | Antibodies binding to hla-a2/wt1 | |
EA201992460A1 (ru) | Антитела-агонисты btla и их применение | |
EA202091569A1 (ru) | Моноклональные антитела и способы их применения | |
EA201492162A1 (ru) | Антитела к трансглютаминазе 2 | |
EA201892094A1 (ru) | АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ |